Comparison of exenatide and acarbose on intra-abdominal fat content in patients with obesity and type-2 diabetes: A randomized controlled trial

What Was Tested

Researchers studied Exenatide in this randomized controlled trial publication.

Who Took Part

The study group was 36 patients.

PubMed indexes the participants as teenagers, young adults, adults, middle-aged adults and older adults, both men and women.

This randomized controlled trial included 36 patients with obesity and type-2 diabetes, who were metformin-unresponsive, receiving metformin/exenatide (GLP-1 group) or metformin/acarbose (control group) for 3 months.

How the Study Was Run

The researchers set it up as a randomized study.

Because people in this Exenatide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

A time span of 3 months appears in the methods.

Primary end-point: intra-abdominal fat content from baseline to 3 months; Secondary end-points: changes in fasting blood glucose, glycated haemoglobin (HbAlc), fasting insulin, blood lipids, weight, body mass index, and inflammatory cytokines from baseline to 3 months.

What Was Measured

The subject headings attached to it are Acarbose, Adiponectin, Blood Glucose, Body Mass Index, Diabetes Mellitus, Type 2, Endpoint Determination and Exenatide.

Author keywords: Inflammatory factors, Intra-abdominal fat and Type-2 diabetes.

What This Means in Plain Language

The paper is a randomized study of Exenatide in 36 patients over 3 months.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2017 (Obesity research & clinical practice), a journal based in Netherlands.

More context: the Exenatide compound page, all human trials.